AUS
NZ
UK
CA
USA
IND
Highlights:
Revenue Growth: UnitedHealth’s revenue for Q3 reached $100.8 billion, marking a 9% increase year-over-year, driven by sales growth in both the UnitedHealth and Optum segments.
Medical Care Ratio: The medical care ratio stood at 85.2%, higher than the previous year's 82.3% and exceeding expectations of a 200 basis points increase.
Revised Earnings Outlook: The company narrowed its 2024 earnings guidance from a range of $27.50 to $28.00 per share to $27.50 to $27.75 per share, with a 2025 top-end earnings forecast of $30, falling short of consensus estimates exceeding $31.
UnitedHealth Group (NYSE:UNH) demonstrated resilience in Q3, outperforming revenue and earnings expectations. The Optum segment led revenue growth, reflecting strong demand for its services. However, the increase in the medical care ratio and the contraction of the operating margin by 60 basis points to 8.6% raised concerns among investors. The lower-than-expected earnings guidance for the next two years indicated persistent challenges related to rising medical costs, which could hinder performance in upcoming quarters.
Market Reaction and Valuation
The decline in UNH stock post-announcement underscores investor disappointment with the company's outlook. Analysts have adjusted their estimates accordingly, projecting a valuation of $552 per share, closely aligned with its current trading price around $560. This valuation reflects a 20x P/E multiple based on anticipated earnings of $27.65 for the full year 2024, slightly below the historical average P/E ratio over the past three years.
Despite a 12% rise in UNH stock this year, it has lagged behind the broader S&P 500 index, which is up 22%. While UnitedHealth has consistently increased its value over the past three years, it has struggled to consistently outperform the market. In contrast, the Trefis High Quality (HQ) Portfolio has provided higher returns with lower volatility, indicating that a diversified approach may yield better long-term results.
In summary, while UnitedHealth Group has shown robust financial performance in Q3, its cautious outlook and the resulting stock price decline highlight the challenges facing the company in a competitive healthcare landscape.
